One-Offs Lift Dr Reddy’s In Q2
Indian Firm Is Eyeing US Opportunities For Its Rival To Suboxone
One-offs aided Dr Reddy’s performance in the second quarter although US growth was flat amid challenges including the recall of ranitidine. But the Indian firm is enthused about fresh potential opportunities for generic Suboxone in the US in view of Indivior’s intent to discontinue its authorized generic.
